BACKGROUND: Podocyturia, i.e. urinary loss of viable podocytes, may serve as a diagnostic tool for pre-eclampsia and as a marker of active renal disease. The current method to detect podocyturia is technically complex, lengthy and requires a high level of expertise for interpretation. The aim of this study was to develop a new technique for the identification of urinary podocytes, based on the detection of podocyte-specific tryptic peptides by liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS), which will provide an operator-independent and highly reproducible method. METHODS AND RESULTS: The diagnosis of pre-eclampsia was confirmed in the presence of hypertension (>140/90 mmHg) and proteinuria >0.3 g/24 h urine. The diagnosis of HELLP was confirmed based on the accepted clinical criteria of hemolysis, elevated liver enzymes and low platelet count. Random urine samples within 24 h prior to delivery were collected and centrifuged. One half of the sediment was cultured for 24 h to select for viable cells and then stained with a podocin antibody, followed by a secondary fluorescein isothiocyanate-labeled antibody to identify podocytes. The second half of the pellet was solubilized, digested and analyzed by LC-MS/MS using an internal standard. We have recruited 13 patients with pre-eclampsia and 6 patients with pre-eclampsia/HELLP syndrome. The presence of podocytes was confirmed in all patients by the podocyte culture method. In the respective samples, the presence of a podocin-specific tryptic peptide was confirmed with LC-MS/MS technology. CONCLUSION: The LC-MS/MS method is a reliable technology for the identification of urinary podocytes, based on the presence of podocyte-specific proteins in the urine.
RCT Entities:
BACKGROUND: Podocyturia, i.e. urinary loss of viable podocytes, may serve as a diagnostic tool for pre-eclampsia and as a marker of active renal disease. The current method to detect podocyturia is technically complex, lengthy and requires a high level of expertise for interpretation. The aim of this study was to develop a new technique for the identification of urinary podocytes, based on the detection of podocyte-specific tryptic peptides by liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS), which will provide an operator-independent and highly reproducible method. METHODS AND RESULTS: The diagnosis of pre-eclampsia was confirmed in the presence of hypertension (>140/90 mmHg) and proteinuria >0.3 g/24 h urine. The diagnosis of HELLP was confirmed based on the accepted clinical criteria of hemolysis, elevated liver enzymes and low platelet count. Random urine samples within 24 h prior to delivery were collected and centrifuged. One half of the sediment was cultured for 24 h to select for viable cells and then stained with a podocin antibody, followed by a secondary fluorescein isothiocyanate-labeled antibody to identify podocytes. The second half of the pellet was solubilized, digested and analyzed by LC-MS/MS using an internal standard. We have recruited 13 patients with pre-eclampsia and 6 patients with pre-eclampsia/HELLP syndrome. The presence of podocytes was confirmed in all patients by the podocyte culture method. In the respective samples, the presence of a podocin-specific tryptic peptide was confirmed with LC-MS/MS technology. CONCLUSION: The LC-MS/MS method is a reliable technology for the identification of urinary podocytes, based on the presence of podocyte-specific proteins in the urine.
Entities:
Keywords:
mass spectrometry; podocyturia; pre-eclampsia
Authors: N Boute; O Gribouval; S Roselli; F Benessy; H Lee; A Fuchshuber; K Dahan; M C Gubler; P Niaudet; C Antignac Journal: Nat Genet Date: 2000-04 Impact factor: 38.330
Authors: D B Donoviel; D D Freed; H Vogel; D G Potter; E Hawkins; J P Barrish; B N Mathur; C A Turner; R Geske; C A Montgomery; M Starbuck; M Brandt; A Gupta; R Ramirez-Solis; B P Zambrowicz; D R Powell Journal: Mol Cell Biol Date: 2001-07 Impact factor: 4.272
Authors: Sharon E Maynard; Jiang-Yong Min; Jaime Merchan; Kee-Hak Lim; Jianyi Li; Susanta Mondal; Towia A Libermann; James P Morgan; Frank W Sellke; Isaac E Stillman; Franklin H Epstein; Vikas P Sukhatme; S Ananth Karumanchi Journal: J Clin Invest Date: 2003-03 Impact factor: 14.808
Authors: Arndt T Petermann; Ron Krofft; Mary Blonski; Keiju Hiromura; Michael Vaughn; Raimund Pichler; Sian Griffin; Takehiko Wada; Jeffrey Pippin; Raghu Durvasula; Stuart J Shankland Journal: Kidney Int Date: 2003-10 Impact factor: 10.612
Authors: Thierry H Le Jemtel; Indranee Rajapreyar; Michael G Selby; Brian Payne; David R Barnidge; Natasa Milic; Vesna D Garovic Journal: Cardiorenal Med Date: 2015-02-28 Impact factor: 2.041
Authors: Iasmina M Craici; Steven J Wagner; Kent R Bailey; Patrick D Fitz-Gibbon; Christina M Wood-Wentz; Stephen T Turner; Suzanne R Hayman; Wendy M White; Brian C Brost; Carl H Rose; Joseph P Grande; Vesna D Garovic Journal: Hypertension Date: 2013-03-25 Impact factor: 10.190
Authors: Philip Webster; Louise M Webster; H Terence Cook; Catherine Horsfield; Paul T Seed; Raquel Vaz; Clara Santos; Isabelle Lydon; Michele Homsy; Liz Lightstone; Kate Bramham Journal: Clin J Am Soc Nephrol Date: 2016-12-09 Impact factor: 8.237
Authors: Wendy M White; Angelica T Garrett; Iasmina M Craici; Steven J Wagner; Patrick D Fitz-Gibbon; Kim A Butters; Brian C Brost; Carl H Rose; Joseph P Grande; Vesna D Garovic Journal: PLoS One Date: 2014-03-24 Impact factor: 3.240
Authors: Iasmina M Craici; Steven J Wagner; Tracey L Weissgerber; Joseph P Grande; Vesna D Garovic Journal: Kidney Int Date: 2014-02-26 Impact factor: 10.612